

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 to 26. (Canceled)

27. (Previously presented) A solid oral pharmaceutical composition comprising an acid sensitive agent and a disintegrant which is present in an amount of at least 15% by weight based on the total weight of the composition, wherein the disintegrant is a member selected from the group consisting of crospovidone, sodium starch glycolate, carboxymethylcellulose sodium, sodium alginate, and a mixture thereof.
28. (Previously presented) A solid oral pharmaceutical composition according to claim 27 wherein said acid sensitive agent is poorly soluble in aqueous media at 25°C.
29. (Previously presented) A solid oral pharmaceutical composition according to claim 27 wherein said acid sensitive agent has a solubility in aqueous media of less than 1% at 25°C.
30. (Previously presented) A solid oral pharmaceutical composition according to claim 29 wherein the acid sensitive agent is a serotonergic compound.
31. (Currently amended) A solid oral pharmaceutical composition according to claim 30 wherein the acid sensitive agent said serotonergic compound is selected from the group consisting of a 5-HT₄ receptor agonist and a 5-HT₄ receptor partial agonist.
32. (Currently amended) A solid oral pharmaceutical composition according to claim 31 wherein the acid sensitive agent said serotonergic compound is a 5-HT₄ receptor partial agonist.
33. (Previously presented) A solid oral pharmaceutical composition of claim 32 wherein the 5-HT₄ receptor partial agonist is 3-(5-methoxy-1H-indol-3-yl-methylene)-N-pentylcarbazimidamide or a pharmaceutically acceptable salt form thereof.
34. (Previously presented) A solid oral pharmaceutical composition of claim 33 wherein the 5-HT₄ receptor partial agonist is a maleate salt of 3-(5-methoxy-1H-indol-3-yl-methylene)-N-pentylcarbazimidamide.

35. (Previously presented) A solid oral pharmaceutical composition according to claim 34 wherein the disintegrant is crospovidone.

36. (Previously presented) A solid oral pharmaceutical composition according to claim 35 comprising a lubricant.

37. (Previously presented) A solid oral pharmaceutical composition according to claim 36 wherein the lubricant comprises a glyceryl mono fatty acid.

38. (Previously presented) A solid oral pharmaceutical composition according to claim 36 wherein the lubricant comprises a mixture of glyceryl monostearate and polyethylene glycol.

39. (Previously presented) A solid oral pharmaceutical composition according to claim 38 comprising a surfactant.

40. (Previously presented) A solid oral pharmaceutical composition according to claim 39 wherein the surfactant is a member selected from the group consisting of a polyoxyethylene-sorbitan-fatty acid ester, a polyoxyethylene fatty acid ester, a polyoxyethylene-polyoxypropylene block co-polymer, a reaction product of a natural or hydrogenated castor oil and ethylene oxide, dioctylsuccinate, di-[2-ethylhexyl]-succinate, a propylene glycol mono-fatty acid, and a propylene glycol di-fatty acid.

41. (Previously presented) A solid oral pharmaceutical composition according to claim 40 wherein the surfactant comprises a polyoxyethylene-polyoxypropylene block co-polymer.

42. (Previously presented) A solid oral pharmaceutical composition according to claim 41 comprising lactose and hydroxypropylmethylcellulose.

43. (Previously presented) A solid oral pharmaceutical composition of claim 35, wherein said pharmaceutical composition has dissolution characteristics in water or USP buffers pH 6.8 and 7.5 of:

time (minutes)	amount (percentage)
5	30 - 90
15	80 - 100
30	95 - 100
60	100.

44. (Previously presented) A solid oral pharmaceutical composition comprising an acid sensitive agent and a disintegrant which is present in an amount between 20% and 60% by weight based on the total weight of the composition, wherein the disintegrant is carboxymethylcellulose calcium.

45. (Previously presented) A solid oral pharmaceutical composition according to claim 44 wherein the acid sensitive agent is a maleate salt of 3-(5-methoxy-1H-indol-3-yl-methylene)-N-pentylcarbazimidamide.

46. (Previously presented) A solid oral pharmaceutical composition comprising an acid sensitive agent and a disintegrant which is present in an amount between 30% and 50% by weight based on the total weight of the composition, wherein the disintegrant is pregelatinized starch.

47. (Previously presented) A solid oral pharmaceutical composition according to claim 46 wherein the acid sensitive agent is a maleate salt of 3-(5-methoxy-1H-indol-3-yl-methylene)-N-pentylcarbazimidamide.

48. (Previously presented) A solid oral pharmaceutical composition according to claim 27 wherein said composition is a tablet.

49. (Previously presented) A solid oral pharmaceutical composition according to claim 33 wherein said composition is a tablet.

50. (Previously presented) A solid oral pharmaceutical composition according to claim 35 wherein said composition is a tablet.

51. (Previously presented) A solid oral pharmaceutical composition according to claim 45 wherein said composition is a tablet.

52. (Previously presented) A solid oral pharmaceutical composition according to claim 47 wherein said composition is a tablet.